InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,534.80
(
0.93%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,667.95
(
0.27%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120657
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 73881

Thursday, 04/16/2009 6:04:05 PM

Thursday, April 16, 2009 6:04:05 PM

Post# of 253509
VRTX just started a second 3-day VCH-222 phase-1 monotherapy study in 32 treatment-naïve genotype-1 patients. VRTX’s CMO said on today’s CC that the previous 3-day VCH-222 study that VRTX touted as the main impetus for the ViroChem acquisition (#msg-36022752) contained only 5 patients!

Today’s CC made it crystal clear that VCH-222 is VRTX’s lead polymerase inhibitor; VCH-759, although further advanced than VCH-222, has been relegated to backup status and will be pursued only if VCH-222 falters.

Today’s PR (including the 1Q09 financial results):
http://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-14949364.html


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up